Maintenance avelumab after second-line chemo for advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a maintenance drug called avelumab can help keep advanced bladder cancer from growing after you've completed two rounds of chemotherapy. It may help extend the time before the cancer returns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or locally advanced bladder cancer (or upper urinary tract cancer) that has spread or cannot be removed by surgery.
- You have already received two types of treatment: first-line with enfortumab vedotin plus pembrolizumab, and second-line with cisplatin or carboplatin plus gemcitabine (at least 3 cycles).
- Your cancer has not grown during the second-line chemo—it must be stable, partially shrunk, or fully shrunk.
- You have measurable disease (visible on scans) and are expected to live at least 3 more months.
- You are in good physical condition (able to care for yourself) and have adequate organ and bone marrow function.
- You have not had serious side effects from previous immune treatments (except thyroid issues) and any ongoing side effects are mild.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.